Sun Pharmaceutical Industries Ltd. (SUNPHARMA) fundamentals
Sun Pharmaceutical Industries Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as SUNPHARMA (ISIN INE044A01036). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Sun Pharmaceutical Industries Ltd. does
Sun Pharmaceutical Industries Limited is an India-based specialty generic pharmaceutical company with a presence in specialty, generics and consumer healthcare products. The Company's global specialty portfolio spans products in dermatology, ophthalmology, and onco-dermatologym, among others. The Company manufactures and markets a large basket of pharmaceutical formulations across chronic and acute therapies, including generic, branded generics, specialty and complex products, over-the-counter (OTC), antiretrovirals (ARV), Active Pharmaceutical Ingredients (API), and intermediates. Its portfolio spans multiple dosage forms, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids. Its marketed specialty portfolio includes Ilumya/ Ilumetri, Winlevi, Levulan Kerastick + BLU-U, Absorica LD, Odomzo, Cequa, Bromsite, Xelpros, and others. Its portfolio also includes UNLOXCYTTM, an anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma.
Valuation and market data
| Last close | ₹1740.00 |
|---|---|
| Market capitalisation | ₹4.21 lakh crore |
| Enterprise value | ₹4.13 lakh crore |
| P/E (TTM) | 36.40 |
| Price to book | 5.02 |
| Price to sales (TTM) | 3.99 |
| Book value per share | ₹346.70 |
| Dividend yield | 91.95% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Wed Feb 08 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹22,531 crore | ₹3,794 crore | ₹2,623 crore | 10.90 |
| Mar 2025 | ₹23,612 crore | ₹4,976 crore | ₹4,228 crore | 17.60 |
| Mar 2024 | ₹20,829 crore | ₹3,450 crore | ₹2,858 crore | 11.90 |
| Mar 2023 | ₹21,141 crore | ₹1,741 crore | ₹1,691 crore | 7.00 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Sep 2026:
| Promoters | 52.7% |
|---|---|
| Foreign institutions (FII) | 14.4% |
| Mutual funds | 13.0% |
| Other domestic institutions | 9.3% |
| Retail and others | 10.7% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.